1. Market Research
  2. > Pharmaceutical Market Trends
Prime Editing and CRISPR Market by Service, Application, and End User : Global Opportunity Analysis and Industry Forecast, 2021––2030

Prime Editing and CRISPR Market by Service, Application, and End User : Global Opportunity Analysis and Industry Forecast, 2021––2030

  • June 2021
  • 271 pages
  • ID: 6126668
  • Format: PDF
  • Allied Market Research


Table of Contents

Prime Editing and CRISPR Market by Service (Cell Line Engineering, Genome Regulation, Gene Editing, and Gene-Modified Cell Therapy), Application (Biomedical Research & Therapy, Agricultural Research, and Others), and End User (Academic Institutes, Biotechnology & Pharma Companies, and Contract Research Organizations): Global Opportunity Analysis and Industry Forecast, 2021––2030

The global prime editing and CRISPR market was valued at $2,694.2 million in 2020, and is estimated to reach $23,493.0 million by 2030, growing at a CAGR of 24.3% from 2021 to 2030.

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology is a genetic tool used for editing of genome. Prime editing is considered as the developed version of CRISPR/Cas9 genome editing technology. It is a genome editing technology, which uses fusion protein of Cas9-nickase and reverse transcriptase for treatment of genetic defects. It is a new molecular gadget capable of removing and cutting any base pair and adding long segments of DNA without breaking both strands of the helix. Prime editing and CRISPR are used as molecular scissors to develop new therapies for treatment of chronic and genetic diseases. This technology helps in the treatment of rare genetic disease such as sickle cell anemia, cystic fibrosis, correction in point mutation and chronic disease such as lung cancer.

The global prime editing and CRISPR market is majorly driven by an alarming increase in prevalence of genomic and chronic diseases such as sickle cell anemia, cystic fibrosis and lung cancer; rise in government funds for genomic projects; surge in demand for genetically mutated crops; advancements in R&D of genes; and rise in awareness regarding genetic engineering. For instance, according to the World Health Organizations (WHO), in 2020, approximately, 10 million people dieddue to various types of cancer. As per data published by a Cystic fibrosis foundation (Cff), in 2019, a total of 70,000 population in the world was diagnosed with cystic fibrosis and more than 1000 new cases of cystic fibrosis were reported each year. Moreover, surge in demand for genetic engineering in biomedical research and rise in need for gene editing drive growth of the market. Thus, increase in prevalence of genetic-based disease and surge in demand for gene manipulation are the factors expected to propel growth of the market.
Rise in funding from private & government organizations to genomic project and increase in application in genetically mutated crops are the major factors that drive the growth of the global prime editing and CRISPR market. Moreover, surge in incidences of diseases such as cancer significantly contributes toward the market growth, owing to the fact that gene insertion and deletion technique is used in treatment of several chronic diseases. Rise in genomic research activities acts as a key driving force of the global market. Furthermore, governments are taking multiple initiatives to support regenerative medical research, which is expected to boost the market growth. Moreover, in 2021, SingHealth Duke-NUS Academic Medical Centre launched advanced regenerative medicine and introduced cellular therapy to enhance patient care. The project aims to explore regenerative cell therapy for treatment of blood cancers, heart failure, and eye degeneration. On the contrary, advancements in R&D for genetic engineering technology in emerging nations are anticipated to provide lucrative opportunities for the market expansion. For instance, in 2021, Scientist at US San Francisco, UC Berkeley launched first clinical trial of CRISPR gene correction therapy in patients suffering from sickle cell disease.

On the contrary, lack of safety concerns and ethical issues regarding gene editing in human germline are the factors anticipated to hinder the market growth during the forecast period. Decrease in cost of DNA is sequenced, which leads to enhancement of genomic research project and increase in research expenditure. This encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity for the prime editing and CRISPR market.

The global prime editing and CRISPR market is segmented into service, application, end user, and region. By service, the market is categorized into cell line engineering, genome regulation, gene editing and gene-modified cell therapy. By application, it is divided into biomedical research & therapy, agricultural research, and others. By end user, the market is bifurcated into academic institutions, biotechnology & pharma companies, and contract research organizations. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global prime editing and CRISPR market are Beam Therapeutics, CRISPR Therapeutics, GenScript Biotech, Horizon Discovery, Integrated DNA Technologies (IDT), Intellia Therapeutics Inc., Inscripta, Precision Bioscience, Sangoma Therapeutics, and Synthego Corporation.

? The report provides an in-depth analysis of the global prime editing and CRISPR market size along with the current trends and future estimations to elucidate the imminent investment pockets.
? It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
? A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
? The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global prime editing and CRISPR market.


By Service
• Cell Line Engineering
• Genome Regulation
• Gene Editing
• Gene-Modified Cell Therapy

By Application
• Biomedical Research & Therapy
• Agricultural Research
• Others

By End User
• Academic Institutes
o Biomedical Research & Therapy
o Agricultural Research
o Others
• Biotechnology & Pharma Companies
o Biomedical Research & Therapy
o Agricultural Research
o Others
• Contract Research Organizations
o Biomedical Research & Therapy
o Agricultural Research
o Others

By Region
o North America
o Europe
Rest of Europe
o Asia-Pacific
South Korea
Rest of Asia-Pacific
Saudi Arabia
South Africa
Rest of LAMEA

• Beam Therapeutics
• CRISPR Therapeutics
• GenScript Biotech
• Horizon Discovery
• Integrated DNA Technologies (IDT
• Intellia Therapeutics Inc.,
• Inscripta
• Precision Bioscience
• Sangoma Therapeutics
• Synthego Corporation

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on